Berkshire Hathaway Inc. (BRK-A) vs Eli Lilly and Company (LLY)
See how Berkshire Hathaway Inc. and Eli Lilly and Company differ across market data and performance, so you can decide which asset best fits your strategy.
$756,650
NYSE
$1,156.73
NYSE
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.
View Full PageKey Metrics Comparison
Berkshire Hathaway Inc.BRK-A
Market Cap$1.08T
Price$756,650
24h Change-0.18%
24h Volume$160
Employees387,800
Shares OutstandingN/A
Eli Lilly and CompanyLLY
Market Cap$1.032T
Price$1,156.73
24h Change-1.52%
24h Volume$3.03M
Employees50,000
Shares Outstanding944,818,881
Category Performance
Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.
Market Share
Share of combined market cap
BRK-A
51.1%LLY
48.9%Volume Share
Share of combined 24h volume
BRK-A
1.0%LLY
100.0%24h Performance
Price change over last 24 hours
BRK-A
-0.18%LLY
-1.52%Price Comparison
Berkshire Hathaway Inc.
Eli Lilly and Company